Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Wofsy

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Biorxiv : the Preprint Server for Biology|May 25, 2026
Serum proteomic atlas reveals distinct molecular signatures of lupus nephritis activity, chronicity, and treatment responseRufei Lu, Catriona A Wagner, Andrea Fava, et al.
Rheumatology (Oxford, England)|March 26, 2024
Extrarenal symptoms associate with worse quality of life in patients enrolled in the AMP RA/SLE Lupus Nephritis NetworkPhilip M Carlucci, Katherine Preisinger, Kristina K Deonaraine, et al.
Arthritis Research & Therapy|February 20, 2024
Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: data from the Accelerating Medicines Partnership Lupus NetworkPeter M Izmirly, Mimi Y Kim, Philip M Carlucci, et al.
Arthritis Care & Research|October 6, 2025
Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to TreatmentAndrea Fava, Catriona A Wagner, Carla J Guthridge, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 6, 2020
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus NephritisYemil Atisha-Fregoso, Susan Malkiel, Kristina M Harris, et al.
JCI Insight|September 20, 2019
PD-1hiCXCR5- T peripheral helper cells promote B cell responses in lupus via MAF and IL-21Alexandra V Bocharnikov, Joshua Keegan, Vanessa S Wacleche, et al.
JCI Insight|January 23, 2024
Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritisAndrea Fava, Jill Buyon, Laurence Magder, et al.
Lupus Science & Medicine|August 14, 2021
Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE NetworkKristina K Deonaraine, Philip M Carlucci, Andrea Fava, et al.
The Journal of Experimental Medicine|September 3, 2025
A human-mouse atlas of intrarenal myeloid cells identifies conserved disease-associated macrophages in lupus nephritisPaul J Hoover, Chirag Raparia, David J Lieb, et al.
Rheumatology (Oxford, England)|February 25, 2022
High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines PartnershipPhilip M Carlucci, Jessica Li, Andrea Fava, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Biorxiv : the Preprint Server for Biology|May 25, 2026
Serum proteomic atlas reveals distinct molecular signatures of lupus nephritis activity, chronicity, and treatment responseRufei Lu, Catriona A Wagner, Andrea Fava, et al.
Rheumatology (Oxford, England)|March 26, 2024
Extrarenal symptoms associate with worse quality of life in patients enrolled in the AMP RA/SLE Lupus Nephritis NetworkPhilip M Carlucci, Katherine Preisinger, Kristina K Deonaraine, et al.
Arthritis Research & Therapy|February 20, 2024
Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: data from the Accelerating Medicines Partnership Lupus NetworkPeter M Izmirly, Mimi Y Kim, Philip M Carlucci, et al.
Arthritis Care & Research|October 6, 2025
Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to TreatmentAndrea Fava, Catriona A Wagner, Carla J Guthridge, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 6, 2020
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus NephritisYemil Atisha-Fregoso, Susan Malkiel, Kristina M Harris, et al.
JCI Insight|September 20, 2019
PD-1hiCXCR5- T peripheral helper cells promote B cell responses in lupus via MAF and IL-21Alexandra V Bocharnikov, Joshua Keegan, Vanessa S Wacleche, et al.
JCI Insight|January 23, 2024
Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritisAndrea Fava, Jill Buyon, Laurence Magder, et al.
Lupus Science & Medicine|August 14, 2021
Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE NetworkKristina K Deonaraine, Philip M Carlucci, Andrea Fava, et al.
The Journal of Experimental Medicine|September 3, 2025
A human-mouse atlas of intrarenal myeloid cells identifies conserved disease-associated macrophages in lupus nephritisPaul J Hoover, Chirag Raparia, David J Lieb, et al.
Rheumatology (Oxford, England)|February 25, 2022
High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines PartnershipPhilip M Carlucci, Jessica Li, Andrea Fava, et al.
Pageof 6